Now
Available
16% African American
5% Other
2% Asian
77% Caucasian
Other preliminary findings demonstrate
improved progression-free survival with
triplet therapy versus doublet therapy.
Research also indicates improved
Demographics
of CoMMpass
Study Patients
progression-free survival with triplet
therapy followed by stem cell transplant
compared to triplet therapy alone.
Why is it important?
As the MMRF CoMMpass Study data
This article is based on
What have we learned?
continues to mature, we anticipate that
Important findings have begun to
questions most important to patients,
emerge from the MMRF CoMMpass
including: Is my genomic profile predictive?
Study. To begin, we’ve validated that
How is my disease doing? Should I be on
enrollees in the study proportionally
three drugs? Should I do a transplant? If
match the multiple myeloma community
Future of Multiple Myeloma
and when I relapse, what actions should
as a whole in terms of age and ethnicity.
I take? Similarly, for clinicians, the
Research.
Based on the seventh interim analysis
MMRF CoMMpass Study should begin
(IA7), the average age was 64 years,
to answer questions such as: How and
77% were Caucasian, 16% African
when should I combine therapies? How
American, 2% Asian, and 5% all other.
should I sequence therapy? Which clinical
white paper, go to
Having African Americans represented
and genomic variables predict treatment
is important, given that they get
response? What is the role of maintenance
themmrf.org/commpassdl
multiple myeloma more often than the
therapy when the patient is experiencing
general population, and we’re trying to
a complete response to therapy?
understand why.
this data will help to answer some of the
The MMRF CoMMpass
Study in Context: A Look
SM
at the Past, Present, and
To receive a copy
of this newly published
The MMRF’s Precision Medicine Model,
At the annual meeting of the American
with the MMRF CoMMpass Study as
Society of Hematology (ASH) in 2015,
its ground-breaking cornerstone, will
seven MMRF CoMMpass Study-related
continue to enable timely, meaningful
abstracts were presented on a range of
progress in the field of multiple
topics such as initiating trunk mutations
myeloma. The data-rich study has the
I t is our hope that the MMRF
and distinct molecular subtypes,
potential to impact our understanding
symptom burden in older patients with
of underlying disease mechanisms as
CoMMpass Study will help to
multiple myeloma, and associations
well as to allow us to identify new drug
answer some of the questions
between performance status and
targets, understand more about how to
most important to patients,
health-related quality of life.
combine and how to sequence therapy,
and identify treatment trends, among
other benefits.
M M RF C O M M PAS S S T U DY
such as, “Is my genomic
profile predictive?”
7